JP2008503591A5 - - Google Patents

Download PDF

Info

Publication number
JP2008503591A5
JP2008503591A5 JP2007518253A JP2007518253A JP2008503591A5 JP 2008503591 A5 JP2008503591 A5 JP 2008503591A5 JP 2007518253 A JP2007518253 A JP 2007518253A JP 2007518253 A JP2007518253 A JP 2007518253A JP 2008503591 A5 JP2008503591 A5 JP 2008503591A5
Authority
JP
Japan
Prior art keywords
alkyl
heteroaryl
mono
aryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007518253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008503591A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/022157 external-priority patent/WO2006002284A1/en
Publication of JP2008503591A publication Critical patent/JP2008503591A/ja
Publication of JP2008503591A5 publication Critical patent/JP2008503591A5/ja
Pending legal-status Critical Current

Links

JP2007518253A 2004-06-22 2005-06-22 ユビキチンリガーゼ阻害剤 Pending JP2008503591A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58226104P 2004-06-22 2004-06-22
US64610205P 2005-01-21 2005-01-21
PCT/US2005/022157 WO2006002284A1 (en) 2004-06-22 2005-06-22 Ubiquitin ligase inhibitors

Publications (2)

Publication Number Publication Date
JP2008503591A JP2008503591A (ja) 2008-02-07
JP2008503591A5 true JP2008503591A5 (enExample) 2008-08-14

Family

ID=34979690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518253A Pending JP2008503591A (ja) 2004-06-22 2005-06-22 ユビキチンリガーゼ阻害剤

Country Status (4)

Country Link
US (1) US20050282818A1 (enExample)
EP (1) EP1758873A1 (enExample)
JP (1) JP2008503591A (enExample)
WO (1) WO2006002284A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
WO2006084281A1 (en) * 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
WO2006105127A2 (en) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
AU2013203433B2 (en) * 2006-08-08 2016-07-28 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ME02789B (me) 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
WO2008115259A2 (en) * 2006-08-10 2008-09-25 Rigel Pharmaceuticals, Inc. Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases
EP2086999B1 (en) * 2006-11-02 2013-01-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof
ES2304112B1 (es) * 2007-02-23 2009-08-13 Universidad De Zaragoza Uso de compuestos como inhibidores de la flavodoxina de helicobacter.
ES2304221B1 (es) * 2007-03-02 2009-09-11 Universidad De Zaragoza Composicion para el tratamiento de enfermedades infecciosas causadas por helicobacter.
ES2304220B1 (es) * 2007-03-02 2009-09-11 Universidad De Zaragoza Composicion para el tratamiento de enfermedades infecciosas.
WO2008124838A1 (en) * 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
GB0717982D0 (en) * 2007-09-14 2007-10-24 Univ Durham Method and means relating to multiple herbicide resistance in plants
JP2011510033A (ja) * 2008-01-25 2011-03-31 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 化合物
US8673910B2 (en) * 2008-06-30 2014-03-18 H. Lee Moffitt Cancer Center And Research Institute Proteasome inhibitors for selectively inducing apoptosis in cancer cells
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
WO2010102286A2 (en) * 2009-03-06 2010-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome inhibitors having chymotrypsin-like activity
US20120122896A1 (en) * 2009-05-08 2012-05-17 Pike Pharma Gmbh 2,1,3-benzoxadiazol derivatives for the inhibition of influenza a and b virus and respiratory syncytial virus replication
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドPfizer Limited 化学化合物
ES2659763T3 (es) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
MY166889A (en) 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
WO2013052943A2 (en) * 2011-10-06 2013-04-11 The Regents Of The University Of Michgian Small molecule inhibitors of mcl-1 and uses thereof
ES2396764B1 (es) * 2011-11-02 2013-12-19 Universidad Autónoma de Madrid FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES.
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
GB201212456D0 (en) 2012-07-12 2012-08-29 Univ Sheffield Treatment of muscular dystrophy
BR112015003824B1 (pt) * 2012-08-24 2022-10-04 Treventis Corporation Composto, composição farmacêutica e uso do composto
WO2014179734A1 (en) 2013-05-02 2014-11-06 The Regents Of The University Of Michigan Deuterated amlexanox
WO2014179755A2 (en) * 2013-05-02 2014-11-06 E3X Bio Method for identifying modulators of ubiquitin ligases
WO2015002994A2 (en) 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
PL3110812T3 (pl) * 2014-02-27 2019-10-31 Treventis Corp Związki antyamyloidowe zawierające benzofurazan
EP3129361A4 (en) * 2014-04-11 2017-11-15 Emory University Treatment of neurodegenerative diseases with asparagine endopeptidase (aep) inhibitors and compositions related thereto
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
EP4029859A1 (en) 2014-11-21 2022-07-20 Bsim Therapeutics, S.A. 2-oxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
WO2016203402A1 (en) 2015-06-15 2016-12-22 Bsim2 – Biomolecular Simulations Lda Bis-furan derivatives as transthyretin (ttr) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (fap)
WO2017132538A1 (en) 2016-01-29 2017-08-03 The Regents Of The University Of Michigan Amlexanox analogs
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CN106565694B (zh) * 2016-10-09 2019-10-15 北京化工大学 一种nbd-有机胺类荧光探针及其制备方法和应用
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
US10888564B2 (en) 2017-01-26 2021-01-12 Institute For Cancer Research Inhibitors of HIV-1 integrase multimerization
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
WO2021152601A1 (en) 2020-02-02 2021-08-05 Ramot At Tel-Aviv University Ltd. Novel activators of the lipidating transporter atp binding cassette protein type 1 (abca1) and therapeutic uses thereof
CN113149930B (zh) * 2021-04-16 2022-09-02 天津大学 一种细胞糖转运通道抑制剂
CN113582940B (zh) * 2021-09-07 2022-05-20 四川大学华西医院 一类脂滴特异性荧光探针及其合成方法
CN122459289A (zh) * 2023-12-01 2026-07-24 热点治疗公司 吲唑基-哌啶磺酰胺和相关化合物及其在疗法中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
GB9622386D0 (en) * 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
DE10000739A1 (de) * 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
DE10045599B4 (de) * 2000-09-15 2004-06-03 Wella Ag Haarfärbemittel auf der Basis von 4-Nitro-2,1,3-benzoxadiazol-Derivaten und dessen Verwendung als Farbstoff zum Färben von Haaren
AU2002213467A1 (en) * 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
MXPA04004443A (es) * 2001-11-14 2004-08-11 Merck Patent Gmbh Derivados de pirazol.
GB0215650D0 (en) * 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) * 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
EP1651595A2 (en) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20050130974A1 (en) * 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors

Similar Documents

Publication Publication Date Title
JP7126541B2 (ja) ハンチントンタンパク質のイメージング用プローブ
JP2016514719A5 (enExample)
JP2023010738A (ja) 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体
JP2015502387A5 (enExample)
JP5864589B2 (ja) 細菌トポイソメラーゼii阻害性2−エチルカルバモイルアミノ−1,3−ベンゾチアゾール−5−イル類
JP2018115201A5 (enExample)
JP2018529739A5 (enExample)
JP6424234B2 (ja) 8−(ピペラジン−1−イル)−1,2,3,4−テトラヒドロ−イソキノリン誘導体
JP2016514718A5 (enExample)
JP2018519357A5 (enExample)
JP2015537017A5 (enExample)
JP2016525075A5 (enExample)
JP2018529650A5 (enExample)
CA2651363A1 (en) Triazolopyrazine derivatives useful as anti-cancer agents
JP2016525130A5 (enExample)
JP2016506368A5 (enExample)
JP2017528519A5 (enExample)
JP2017538721A5 (enExample)
JP2015529224A5 (enExample)
HRP20230472T1 (hr) Novi derivati hidroksikiseline, postupak njihove priprave i farmaceutski sastavi koji ih sadrže
JP2013523803A5 (enExample)
JP2017513879A5 (enExample)
JP2016531858A5 (enExample)
JP2020536116A5 (enExample)
JP2013540755A5 (enExample)